ClinicalTrials.gg
RecruitingNCT05315804Updated Feb 28, 2024

Treatment of Intraosseous Periodontal Defects With Amelogenins

An interventional study of MINSD and amelogenins and MINSD in Periodontal Bone Loss and Periodontal Pocket, sponsored by Federico II University. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Federico II University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Alveolar Bone Loss with a site in Italy — 2 open to participants now, 6 under way, none of them phase 3. Alveolar Bone Loss · Italy.

Planned enrollment
17th of 23
22 · median 44
Started
2023
with 4 others
No phase
21 of 30
2 open now
Registered
17th of 30
by date
Lead sponsor
3 of 30
Federico II University

Among the 30 studies in Alveolar Bone Loss with a site in Italy, this one is the 17th largest by planned enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2023, is one of 21 with no phase, and was the 17th registered.

Alveolar Bone Loss

320 studies on the registry are indexed under Alveolar Bone Loss; 79 are open to participants now.

Browse Alveolar Bone Loss studies →

Open to participants now

2 of the 30 studies in Alveolar Bone Loss with a site in Italy are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 47 Alveolar Bone Loss studies recruiting now, 19 (40%) set no upper age limit and 22 (47%) stop at 75 or younger; 4 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Alveolar Bone Loss with a site in Italy, or all of them as a file.
02

Study summary

The aim of the present investigation will be evaluate the healing of periodontal intraosseous defects following Minimally Invasive Non Surgical Debridement (MINSD) and application of amelogenins, compared to MINSD alone.

A total of 22 patients will be enrolled, selected by inclusion and exclusion criteria and randomly divided in two groups: amelogenin (A) and no-amelogenin group (B).

Read the detailed description

The objective of the study will be compare the healing of periodontal intraosseous defects following treatment with Minimally Invasive Non Surgical Debridement (MINSD) and application of amelogenins compared to MINSD alone.

Twenty-two patients with intraosseous periodontal defects will be randomly assigned to treatment with MINSD and application of amelogenins (A Group) or MINSD alone (B Group).

Primary outcome will be "Clinical Attachment Level" (CAL) gain, while the secondary outcomes will be "Probing Depth" (PD), "Gingival Recession" (GR) and "Radiographic Defect Angle" (RDA).

After local anesthesia, in A group MINSD will be performed using an ultrasonic scaler with fine tips and micro-curette; then, amelogenins in gel will be applied in the intraosseous periodontal pockets using a sterile syringe with plasticized needle.

In the B group, only subgingival mechanical debridement (MINSD) will be performed with an ultrasonic scaler with fine tips and micro-curette.

Finally, a polishing paste will be applied to the supra-gingival level in both groups using a rubber cup. Patients of both groups will be recalled every month for professional oral hygiene and, after 6 months, all measurements will be repeated and the final evaluation will be carried out.

03

Conditions studied

  • Periodontal Bone Loss
  • Periodontal Pocket

Keywords

  • Amelogenin
  • Periodontal Therapy
  • Periodontal Bone Loss
  • Intraosseous Bone Defect
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with periodontitis;
  • Age ≥ 18 years old;
  • Presence of at least 10 teeth per arch;
  • Presence of at least two teeth with Probing Depth (PD) ≥ 5 mm per quadrant;
  • Presence of at least one intraosseous pocket;
  • Single-rooted and multi-rooted teeth.

Exclusion criteria

Exclusion Criteria:

  • Patients with systemic diseases;
  • Prolonged antibiotic or anti-inflammatory treatment within 4 weeks prior to periodontal therapy;
  • Pregnant or lactating;
  • Tobacco smokers (≥ 10 cigarettes per day);
  • Multi-rooted teeth with furcation involvement;
  • Third molars.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Amelogenin Group (A)

    Amelogenins in gel will be applied in intraosseous periodontal defects, after Minimally Invasive Non Surgical Debridement (MINSD)

    Other: MINSD and amelogenins

  • Active comparator
    No-amelogenin Group (B)

    Only Minimally Invasive Non Surgical Debridement (MINSD) will be performed

    Other: MINSD

Interventions

  • OtherMINSD and amelogenins

    After local anesthesia, MINSD will be performed using an ultrasonic scaler with fine tips and micro-curette; then, amelogenins in gel will be applied to the intraosseous periodontal pockets using a sterile syringe with plasticized needle.

  • OtherMINSD

    Only subgingival mechanical debridement (MINSD) will be performed with an ultrasonic scaler with fine tips and micro-curette.

06

What researchers measure

Primary outcomes

  1. Change of Clinical Attachment Level (CAL) gain (millimeters)

    Distance from the cementoenamel junction to the bottom of the pocket

    Time frame: baseline and 6 months after periodontal therapy

Secondary outcomes

  1. Change of Probing Depth (PD) (millimeters)

    Distance from the gingival margin to the bottom of the pocket

    Time frame: baseline and 6 months after periodontal therapy

  2. Change of Gingival Recession (GR) (millimeters)

    Distance from gingival margin to the cementoenamel junction

    Time frame: baseline and 6 months after periodontal therapy

  3. Change of Radiographic Defect Angle (RDA) (grade °)

    Radiographic intraosseous angle

    Time frame: baseline and 6 months after periodontal therapy

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Jul 2024, 17 months after the start.

Of 169 non-industry interventional studies with no phase under Alveolar Bone Loss, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 30. This study's planned 17 months is close to that.

Counting every sponsor, half of 169 studies reached it within 18 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2022
First posted
Apr 7, 2022
StartActual
Feb 1, 2023
Primary completionEst.
Jul 1, 2024
CompletionEst.
Oct 1, 2024
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05315804
Responsible party
Luca Ramaglia (Clinical Professor, Federico II University) — Principal investigator
First posted
Apr 7, 2022
Start date
Feb 1, 2023
Primary completion
Jul 1, 2024 (estimated)
Completion
Oct 1, 2024 (estimated)
Last update
Feb 28, 2024

Study contacts

Luca Ramaglia
Contact
luca.ramaglia@unina.it
+393476912911
Luca Ramaglia
principal investigator · Federico II University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion